Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332210 | 0.80 | PDK2 (0.48) | BRD4ESR2GABRG2GABRB3GABRA5 | |
| SCHEMBL17794955 | 0.80 | LRRK2 (0.48) | CNR1CNR2BRD4CCNCCDK8 | |
| SCHEMBL30332345 | 0.78 | PDK2 (0.49) | ESR2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21071834 | 0.78 | AXL (0.47) | CNR1CNR2BRD4SMARCA2SMARCA4 | |
| SCHEMBL23761239 | 0.78 | PIK3CD (0.47) | CNR1CNR2GABRG2GABRB3GABRA5 | |
| SCHEMBL17809687 | 0.76 | BRD4 (0.42) | CNR1CNR2BRD4SMARCA2SMARCA4 | |
| SCHEMBL1880689 | 0.76 | GRIA1 (0.63) | CNR1CNR2BRD4GABRG2GABRB3 | |
| SCHEMBL17806614 | 0.76 | LRRK2 (0.45) | CNR1CNR2BRD4CCNCCDK8 | |
| SCHEMBL23638914 | 0.75 | BRD4 (0.54) | BRD4SMARCA2SMARCA4EPHX2PDK2 | |
| SCHEMBL10094625 | 0.75 | BRD4 (0.54) | BRD4SMARCA2SMARCA4EPHX2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4380930-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023016477-A9 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-04-25 | — | — | WO | disclosed |
| CN-117916235-A | Cyclin dependent kinase inhibitors | 泰州亿腾景昂药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023016477-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016477-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2021160109-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | CNR1 3658/4885CNR2 4173/4885BRD4 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.